Brief: Nkarta Initiates Clinical Trial Of Nkx019 In Lupus Nephritis
27/06/2024 11:03
June 27 (Reuters) - Nkarta Inc NKTX.O :
* NKARTA INITIATES CLINICAL TRIAL OF NKX019 IN LUPUS
NEPHRITIS
WITH FIRST PATIENT IN SCREENING AND ANNOUNCES PIPELINE EXPANSION
TO ADDITIONAL AUTOIMMUNE INDICATIONS
* NKARTA INC: CLINICAL DATA FROM NTRUST-1 AND NTRUST-2
PLANNED FOR
2025
Source text for Eikon: ID:nGNX2GCwFJ
Further company coverage: NKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkarta
See all newsNkarta, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Brief: Nkarta Q2 EPS USD -0.54
Nkarta, Inc. expected to post a loss of 38 cents a share - Earnings Preview
Biotech experts want FDA drug reviews based on science, not politics (updated)